| Title |
Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting
|
|---|---|
| Published in |
European Radiology, January 2017
|
| DOI | 10.1007/s00330-017-4736-9 |
| Pubmed ID | |
| Authors |
John C. Waterton, Meilien Ho, Lars H. Nordenmark, Martin Jenkins, Julie DiCarlo, Gwenael Guillard, Caleb Roberts, Giovanni Buonaccorsi, Geoffrey J. M. Parker, Michael A. Bowes, Charles Peterfy, Herbert Kellner, Peter C. Taylor |
| Abstract |
To determine the repeatability and response to therapy of dynamic contrast-enhanced (DCE) MRI biomarkers of synovitis in the hand and wrist of rheumatoid arthritis (RA) patients, and in particular the performance of the transfer constant K (trans) , in a multicentre trial setting. DCE-MRI and RA MRI scoring (RAMRIS) were performed with meticulous standardisation at baseline and 6 and 24 weeks in a substudy of fostamatinib monotherapy in reducing synovitis compared with placebo or adalimumab. Analysis employed statistical shape modelling to avoid biased regions-of-interest, kinetic modelling and heuristic analyses. Repeatability was also evaluated. At early study termination, DCE-MRI data had been acquired from 58 patients in 19 imaging centres. K (trans) intra-subject coefficient of variation (N = 14) was 30%. K (trans) change demonstrated inferiority of fostamatinib (N = 11) relative to adalimumab (N = 10) after 6 weeks (treatment ratio = 1.92, p = 0.003), and failed to distinguish fostamatinib from placebo (N = 10, p = 0.79). RAMRIS showed superiority of fostamatinib relative to placebo at 6 weeks (p = 0.023), and did not distinguish fostamatinib from adalimumab at either 6 (p = 0.175) or 24 (p = 0.230) weeks. This demonstrated repeatability of K (trans) and its ability to distinguish treatment groups show that DCE-MRI biomarkers are suitable for use in multicentre RA trials. • DCE-MRI biomarkers are feasible in large multicentre studies of joint inflammation. • DCE-MRI K (trans) showed fostamatinib inferior to adalimumab after 6 weeks. • K (trans) repeatability coefficient of variation was 30% multicentre. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 40% |
| Comoros | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 60 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 33% |
| Student > Ph. D. Student | 7 | 11% |
| Professor | 7 | 11% |
| Other | 5 | 8% |
| Student > Bachelor | 3 | 5% |
| Other | 9 | 15% |
| Unknown | 10 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 43% |
| Engineering | 5 | 8% |
| Physics and Astronomy | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Computer Science | 3 | 5% |
| Other | 7 | 11% |
| Unknown | 13 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2017.
All research outputs
#6,610,090
of 24,332,257 outputs
Outputs from European Radiology
#942
of 4,570 outputs
Outputs of similar age
#118,611
of 426,771 outputs
Outputs of similar age from European Radiology
#15
of 34 outputs
Altmetric has tracked 24,332,257 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 4,570 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 426,771 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.